We are pleased to invite investors and analysts to participate in our virtual event on Friday, 4 April 2025, to highlight new results from Roche’s Neurology pipeline including Phase III (EMBARK) Elevidys in DMD 2-year data presented at the Muscular Dystrophy Association conference (MDA) from 16-19 March 2025, as well as Phase IIb (PADOVA) data for prasinezumab in PD and Phase Ib/II (Brainshuttle™) data for trontinemab in AD presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) from 1-5 April 2025. 16:00 - 17:30 CEST / 15:00 - 16:30 BST 10:00 - 11:30 am EDT / 7:00 - 8:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here Agenda Introduction Bruno Eschli, Head of Investor Relations Elevidys PhIII EMBARK 2-year data in DMD Alex Murphy, Senior Clinical Director, Neuromuscular Disorders & Stroke, Roche Prasinezumab PhIIb PADOVA data in early PD Azad Bonni, SVP and Global Head of Neuroscience & Rare Diseases, Roche Pharma Research & Early Development Trontinemab update from Ph Ib/II (Brainshuttle™) in AD Luka Kulic, VP and Global Head of Early Development, Neuroscience & Rare Diseases, Roche Pharma Research & Early Developmentment Q&A Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice

Best regards, Bruno Eschli Head of Investor Relations	Sabine Borngräber Investor Relations Officer
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.